Navigation Links
The Leukemia & Lymphoma Society: Impacting Blood Cancers and Beyond
Date:2/19/2013

s as soon as possible. LLS works in concert with academic investigators, medical centers and pharmaceutical and biotechnology companies to move promising therapies quickly from the laboratory into clinical trials and, ultimately, to patients.

LLS continues to support and fund the world's best and brightest academic scientists and award grants based on merit to advance progress in all areas of blood cancer research, and at all stages from basic science to clinical trials. Through our grants programs we support the development of the next generation of first rate cancer researchers.

Proof of LLS's cure-focused, patient-centered infrastructure is apparent from the allocation of its funds. Last year, 78 percent of the money spent by LLS went to research, patient and community services, advocacy and education. Its co-pay assistance program provided $44.2 million to almost 14,000 patients in need. LLS's Office of Public Policy team advocates for policies that help speed the approval process for new blood cancer therapies and ensure access to quality, affordable and coordinated care for patients.

"Ultimately, cancer affects everyone," said Walter. "We all have an opportunity to impact a cure for this disease now. Someday truly is today."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Key LLS fundraising campaigns include Team In Training, Light The Night, School & Youth, Man & Woman of the Year and Regatta. To reach the widest possible audience, LLS partners with national and regional level companies and brands, including Nike, Disney, Burlington
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
2. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
3. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
4. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
5. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
6. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
7. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
8. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
9. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
10. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
11. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
(Date:2/27/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... patients and health care advocates in the United States ... Rare Disease Day is dedicated to elevating public ... special challenges faced by patients with rare diseases and ... to stand alongside patients and caregivers representing the rare ...
(Date:2/27/2015)... BOSTON , Feb. 27, 2015   PureTech ... identifying, inventing and commercializing disruptive products and technologies in ... Christopher Viehbacher , former CEO and Member of the ... Directors.  "It,s has been a pleasure ... very excited that we will be working together more ...
(Date:2/26/2015)... , Feb. 26, 2015 On behalf of ... affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... lawsuit against Genewiz Inc. in excess of $10 million. ... GenScript,s trade secrets, and that it improperly hired one ... order denying motions for judgment notwithstanding the verdict, a ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... Switzerland, Aug. 21 Roche (SWX: ROG.VX; RO.S),a world-leading ... has extended its offer to acquire all of the,outstanding ... VMSI ),to 5:00 p.m., New York City time on ... to expire at 5:00 p.m., New York City,time, on ...
... and PRAGUE, Czech Republic, Aug. 21 ... organization, today,announced it has completed the acquisition ... (CRO) headquartered in Prague, Czech,Republic. This move ... and,expands its capacity to provide full service ...
... WOODLANDS, Texas, Aug. 21 ,Lexicon Pharmaceuticals, Inc. ... the structure-activity relationship (SAR) of a class ... compounds,under evaluation by the company as potential ... gastrointestinal disorders. LX1031 is currently,under evaluation in ...
Cached Biology Technology:Roche Extends Tender Offer for Ventana 2Roche Extends Tender Offer for Ventana 3Roche Extends Tender Offer for Ventana 4Medpace Strengthens Presence in Central Europe 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25
... at Northwestern University Feinberg School of Medicine played ... approval of Abraxane (paclitaxel protein-bound particles for injectable ... cancer. "The approval means that women with metastatic ... toxicities associated with solvents and will no longer ...
... Hopkins Medical Institutions in Baltimore, Md., reports that whole-body ... identify new, unexpected malignant cancerous tumors in patients, according ... Society of Nuclear Medicine's Journal of Nuclear Medicine. , ... to have cancer," said SNM member Richard L. Wahl, ...
... and Drug Administration (FDA) was "the single greatest obstacle ... safety officer David Graham at an unprecedented roundtable of ... (PLoS) and the Government Accountability Project. , In comments ... Senate Finance Committee, Graham said that, "Nearly 60,000 people ...
Cached Biology News:Nanoparticle Breast Cancer Drug Approved by FDA 2PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment 2Medical whistleblowers speak out 2Medical whistleblowers speak out 3
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The Hybrid Hunter Yeast Two-Hybrid System uses the activation of reporter genes to indicate positive protein-protein interactions. Two reporters are used an auxotrophic marker and lacZ....
Biology Products: